Recent Updates
Recently added Catalysts
NKTR

Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022, after the close of U....

Key Takeaway: SAN FRANCISCO , Oct. 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer,
Price reaction · baseline $53.55 (2022-10-24 close) · hit after-hours · clean, no other NKTR news in the window
day 0 close · peak
+3.1%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO , Oct. 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial results for the third quarter 2022 on Thursday, November 3, 2022 , after the close of U.S.-based financial markets. Howard Robin , President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time .
The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/ . The web broadcast of the conference call will be available for replay through December 3, 2022 .
To access the conference call, please pre-register at Nektar Earnings Call Registration . All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and inflammatory diseases as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .
Last updated: Oct 25, 2022